Back to today’s briefing

Story perspectives

Personalized mRNA Vaccine Slashes Melanoma Spread Risk 60%

6/1/2026

32 7 Full Breakdown

Summary

Story summary

The personalized mRNA vaccine cut melanoma spread risk by almost 60% in a U.S. trial, Dr. Janice Mehnert reported.
The vaccine was produced four to six weeks after surgery and given in nine three-week-spaced doses with pembrolizumab.
Side effects were mild flu-like symptoms that lasted a few days.
A phase-3 trial of about 1,000 patients in the United States and Europe is underway to confirm the findings.

1 of 1

Story summary

The personalized mRNA vaccine cut melanoma spread risk by almost 60% in a U.S. trial, Dr. Janice Mehnert reported.
The vaccine was produced four to six weeks after surgery and given in nine three-week-spaced doses with pembrolizumab.
Side effects were mild flu-like symptoms that lasted a few days.
A phase-3 trial of about 1,000 patients in the United States and Europe is underway to confirm the findings.